Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $8.2 million.

  • Syndax Pharmaceuticals' Net Cash Flow fell 7041.6% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.2 million, marking a year-over-year decrease of 14214.04%. This contributed to the annual value of -$141.3 million for FY2024, which is 16390.11% down from last year.
  • As of Q3 2025, Syndax Pharmaceuticals' Net Cash Flow stood at $8.2 million, which was down 7041.6% from -$45.4 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' 5-year Net Cash Flow high stood at $200.8 million for Q4 2023, and its period low was -$180.8 million during Q1 2024.
  • Its 5-year average for Net Cash Flow is $87736.8, with a median of -$90000.0 in 2025.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 197507.52% in 2022, then skyrocketed by 664199.4% in 2023.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Net Cash Flow stood at $150.5 million in 2021, then plummeted by 98.02% to $3.0 million in 2022, then skyrocketed by 6641.99% to $200.8 million in 2023, then plummeted by 89.51% to $21.1 million in 2024, then crashed by 61.2% to $8.2 million in 2025.
  • Its Net Cash Flow stands at $8.2 million for Q3 2025, versus -$45.4 million for Q2 2025 and -$90000.0 for Q1 2025.